begin
clinic
use
plasmaderiv
protin
concentr
sever
noninfecti
advers
event
ae
transmiss
pathogen
plasmaderiv
protein
concentr
threat
recipi
see
chap
addit
inform
first
antiinfecti
plasma
potein
concentr
standard
igg
prepar
produc
coldethanol
fraction
method
make
except
noninfecti
sever
ae
occur
infecti
ae
rare
report
inde
prior
introduct
mass
screen
infect
marker
plasma
donat
inadvert
transmiss
hiv
recipi
factor
viii
factor
ix
concentr
occur
igg
concentr
obtain
plasma
pool
rare
transmit
hiv
morgenthal
rare
transmiss
restrict
product
expos
low
ph
incid
hiv
incid
hcv
transmiss
igg
concentr
earli
togeth
mani
case
coagul
factor
concentr
transmit
viral
diseas
clearli
demonstr
need
establish
standard
measur
render
plasma
product
pathogen
safe
second
half
author
shift
regulatori
emphasi
scientif
review
process
focu
complianc
current
good
manufactur
practic
cgmp
focu
cgmp
complianc
appli
aspect
plasma
fraction
clinic
use
plasma
product
court
injunct
warn
letter
consequ
paradigm
shift
author
turn
result
paradigm
shift
modern
plasma
industri
oper
steinhardt
strict
implement
recommend
author
result
today
immunoglobulin
concentr
gener
well
toler
safe
regard
transmiss
known
bloodborn
virus
agent
transmiss
spongiform
enceph
tse
even
emerg
reemerg
zoonot
virus
furthermor
moden
igg
concentr
excel
noninfecti
advers
event
record
particularli
use
chronic
condit
manufactur
igg
concentr
flow
process
outlin
fig
along
flowchart
particular
measur
serv
obtain
clinic
toler
achiev
reduct
pathogen
potenti
contamin
start
materi
effort
undertaken
provid
patient
igg
concentr
safe
aspect
outlin
plasma
protein
concentr
typic
prepar
plasma
thousand
donor
inevit
associ
risk
transmit
bloodborn
pathogen
see
chap
therefor
modern
fraction
human
plasma
clinic
use
embed
tight
network
qualiti
assur
qa
put
place
recommend
author
good
manufactur
practic
gmp
part
qa
program
slopecki
et
al
gmp
guidanc
industri
gmp
ensur
fig
strongli
simplifi
outlin
fraction
pool
plasma
pathogen
free
welltoler
igg
concentr
side
fraction
process
start
materi
plasma
product
igg
level
manufactur
gener
larg
volum
plasma
optim
safeti
level
b
plasma
depriv
cryoprecipit
contain
relev
bloodclot
factor
level
c
seri
step
result
crude
igg
concentr
toler
intraven
level
sequenc
step
render
igg
concentr
clinic
well
toler
level
e
lyophil
product
adjust
appropri
concentr
excipi
ad
solut
fill
vial
product
lyophil
liquid
formul
final
similarli
leav
freezedri
process
bottl
lyophiliz
igg
solut
label
readi
ship
pj
consist
product
describ
minim
requir
product
must
fulfil
obtain
market
author
cover
procedur
receipt
materi
product
packag
label
qualiti
control
releas
storag
distribut
procedur
law
gmp
defin
countri
gmp
move
target
current
gmp
cgmp
includ
recent
develop
knowledg
field
technolog
inform
capabl
chang
requir
maintain
good
manufactur
practic
solid
fundament
gmp
element
stateoftheart
plasm
product
good
clinic
practic
gcp
good
laboratori
practic
glp
standard
oper
procedur
sop
train
staff
donor
select
deferr
inventori
hold
mass
screen
donat
infect
marker
serolog
nucleic
acid
amplif
technolog
nat
test
recent
one
compani
ad
isoagglutinin
titer
screen
plasma
donat
order
obtain
plasma
pool
chromatograph
fraction
low
isoagglutinin
antia
antib
siani
et
al
inprocess
control
product
paramet
infect
marker
valid
studi
manufactur
step
dedic
pathogen
reduct
polish
step
clinic
toler
pathogen
reduct
label
shipment
clean
segreg
look
back
pharmacovigil
audit
intern
extern
inspector
plasma
fraction
compliant
gmp
undergon
process
valid
manufactur
step
process
valid
help
ensur
system
perform
intend
manner
process
valid
ensur
product
requir
potenc
puriti
safeti
paramet
singl
process
step
defin
laboratori
scale
paramet
obtain
valid
process
help
defin
element
process
control
provid
mechan
ongo
qualiti
assur
qualiti
control
train
compet
review
continu
improv
preti
ensur
pathogen
safeti
plasma
product
need
tripod
measur
donor
select
mass
screen
pathogen
marker
pathogen
elimin
inactiv
manufactur
exampl
implement
pathogen
safeti
plasma
product
view
european
medicin
agenc
cite
safeti
product
demonstr
experiment
valid
studi
laboratori
scale
studi
base
principl
deliber
contamin
intermedi
product
model
virus
given
stage
manufactur
process
monitor
reduct
infect
produc
product
step
consider
time
gmp
introduc
wellestablish
fraction
procedur
place
valid
studi
process
downscal
laboratori
scale
first
step
demonstr
scaleddown
process
mimic
process
product
ie
ideal
ident
process
paramet
furthermor
author
request
least
two
dedic
viru
removalinactiv
step
sequenc
fraction
two
method
repres
two
differ
principl
action
therebi
assur
viru
reduct
complementari
fraction
plasma
fundament
cgmp
appli
full
packag
complementari
recommend
stateoftheart
immunoglobulin
prepar
result
activ
plasma
collect
deliveri
door
custom
perform
document
accord
standard
may
sever
consequ
noncompli
compani
defici
adher
gmp
detect
inspect
compani
lead
consent
decre
sever
deviat
consequ
compani
forc
ceas
distribut
product
http
http
access
april
lead
regulatori
agenc
enforc
adher
qa
fraction
recommend
us
food
drug
administr
fda
http
wwwfdagov
european
medicin
agenc
ema
wwwema
europaeu
countri
agenc
govern
enforc
recommend
list
region
offic
africa
america
eastern
mediterranean
europ
southeast
asia
western
pacif
found
http
wwwwhointmedicinesareasqualitysafetyregulationlegislationlistmrawebsitespdf
access
april
igg
concentr
belong
stabl
blood
product
ensur
qualiti
igg
concentr
start
collect
plasma
correct
handl
cautiou
pool
donor
select
level
fig
plasma
fraction
current
best
practic
igg
concentr
donor
donat
blood
plasma
free
two
type
donat
whole
blood
plasma
collect
centrifug
recov
plasma
plasma
obtain
apheresi
devic
apheresi
sourc
plasma
tabl
epic
sever
decad
ongo
debat
two
way
plasma
collect
higher
ethic
better
biolog
qualiti
reason
step
discuss
book
chapter
howev
acknowledg
apheresi
plasma
collect
volum
upper
end
allow
might
influenc
protein
composit
donat
plasma
laub
et
al
gmp
cover
minim
requir
qualiti
accus
remuner
donat
lesser
qualiti
safeti
apheresi
plasma
collect
fraction
industri
introduc
addit
voluntari
regul
intern
qualiti
plasma
program
iqpp
introduc
qualifi
donor
standard
implement
donor
deferr
registri
drug
abus
screen
qualiti
standard
excel
assur
leadership
qseal
qseal
cover
control
incom
plasma
inventori
hold
nat
test
intermedi
purchas
form
extern
supplier
recov
plasma
specif
qualifi
donor
viral
marker
http
wwwpptaglobalorgsafetyqu
standardsqs
access
june
implement
voluntari
standard
relev
differ
found
pathogen
marker
frequenc
either
type
plasma
donat
emea
summari
main
goal
donor
select
ensur
donor
high
risk
exclud
form
donat
donat
withheld
process
tabl
donor
inform
hiv
posit
final
yet
importantli
plasma
donat
requir
care
handl
prevent
format
accumul
vasoact
eg
prekallikrein
activ
pka
coagul
promot
eg
coagul
factor
fxia
substanc
due
physicochem
properti
remov
manufactur
process
may
remain
imperfect
may
induc
sever
advers
event
donat
allow
total
plasma
protein
content
gl
usa
germani
level
igg
gl
germani
c
eu
assess
everi
fifth
donat
usa
serum
protein
electrophoresi
everi
month
protein
qualiti
donat
donor
donat
high
volum
per
year
low
plasma
protein
content
address
recent
laub
et
al
mass
screen
donat
level
fig
mass
screen
measur
exclud
donat
potenti
contamin
pathogen
viru
es
stabl
blood
product
inherit
particular
risk
transmiss
virus
stare
materi
pool
thousand
individu
donat
tabl
paramet
mass
screen
viru
marker
outlin
tabl
includ
serolog
nucleic
acid
amplif
technolog
nat
test
nat
test
addit
serolog
screen
introduc
order
shorten
time
period
window
donat
window
period
donor
alreadi
harbor
infect
agent
infect
seroconvers
occur
yet
ie
antibodi
format
set
antibodi
titer
detect
valid
serolog
method
introduc
nat
test
estim
risk
undetect
infecti
donat
enter
blood
suppli
drop
given
detail
health
histori
questionnair
rel
current
known
safeti
risk
design
obtain
inform
eg
acut
infect
silent
progress
chronic
ill
elev
risk
acquir
bloodborn
pathogen
eg
social
behavior
sexual
transmit
diseas
tattoo
acupunctur
earbodi
pierc
past
month
receiv
xenotranspl
cornea
anim
origin
treat
pituitari
growth
hormon
human
origin
donor
deferr
eg
donor
travel
live
endem
region
donor
deferr
move
target
yang
et
al
inventori
hold
eg
allow
retriev
plasma
prior
use
new
postdon
inform
becom
avail
regard
donor
health
statu
apheresi
plasma
collect
industri
addit
establish
iqpp
qseal
b
standard
addit
add
qualifi
donor
standard
donor
success
pass
two
donor
medic
histori
screen
requir
viral
test
communitybas
donor
donor
accept
proof
perman
address
use
ppta
sourc
nation
donor
deferr
registri
nddr
help
ensur
defer
donor
donat
plasma
eg
anoth
center
educ
donor
risk
infecti
diseas
educ
avoid
behavior
believ
lead
increas
risk
hiv
infect
personnel
educ
train
standard
profession
medic
facil
criteria
qualiti
assur
viral
marker
standard
plasma
fraction
obtain
remuner
plasmapheresi
donat
addit
voluntari
standard
introduc
correspond
plasmapheresi
collect
industri
minim
risk
infect
remuner
donat
might
harbor
donor
deferr
establish
eg
donor
live
certain
time
given
region
world
receiv
xenotranspl
drug
daignaux
et
al
medic
devic
part
anim
origin
donor
deferr
move
object
yang
et
al
iqpp
intern
qualiti
plasma
program
b
qsael
qualiti
standard
excel
assur
leadership
certif
program
donat
center
compli
implement
viru
reduct
step
fraction
process
plasmaderiv
medicin
product
thorough
enforc
author
rigor
implement
good
manufactur
practic
gmp
rule
proven
transmiss
envelop
virus
report
criteria
invari
present
true
viru
transmiss
stabl
plasma
product
sever
patient
infect
viru
cluster
transmiss
eg
restrict
number
hospit
possibl
identifi
onea
lot
use
affect
hospit
viru
identifi
relev
product
lot
patient
treat
lot
criteria
fulfil
transmiss
plasma
product
pathogen
remain
uncertain
b
hev
infect
genotyp
caus
larg
epidem
tropic
subtrop
region
transmiss
via
fecalor
rout
infect
genotyp
emerg
threat
countri
northern
hemispher
foodborn
diseas
pig
anim
reservoir
zoonot
viru
genotyp
identifi
blood
donor
europ
transfus
associ
hev
infect
report
tamura
et
al
signific
acut
hepat
result
chronic
hev
infect
immun
compromis
patient
mott
et
al
immunocompet
patient
hev
infect
associ
neurolog
complic
continu
fig
addit
minim
requir
given
gmp
manufactur
request
human
parvoviru
hav
nat
test
plasma
donat
nat
test
perform
minipool
larg
autom
aliquot
bar
code
label
pilot
tube
transfer
eg
micro
titer
plate
xy
layout
aliquot
unequivoc
associ
individu
donat
start
nat
test
aliquot
aliquot
pool
undergo
valid
amplif
part
pathogen
genom
result
genom
equival
quantifi
size
minipool
depend
amplif
effici
minim
infecti
dose
given
pathogen
case
minipool
reactiv
pool
repeat
time
row
column
row
column
pool
nogueira
et
al
venturi
et
al
prenat
infect
associ
microcephali
infect
adult
fatal
associ
syndrom
sever
thrombocytopenia
f
transmiss
nonleukocyt
deplet
erythrocyt
concentr
might
repres
risk
transmiss
four
possibl
transmiss
event
nonleukocytedeplet
erythrocyt
concentr
report
one
case
probabl
transmiss
like
rout
infect
contamin
plasmaderiv
factor
viii
concentr
g
may
report
two
patient
receiv
bloodclot
factor
concentr
die
form
scjd
post
electron
urwin
et
al
causal
link
treatment
plasma
product
develop
scjd
establish
mass
screen
agent
variant
creutzfeldtjakob
diseas
becom
feasibl
howev
practic
jackson
et
al
reactiv
xy
layout
allow
identif
reactiv
donat
contamin
donat
withheld
pool
destroy
safe
plasma
fraction
start
pool
individu
donat
appropri
volum
start
fraction
process
inprocess
control
perform
ascertain
absenc
potenti
contamin
virus
tabl
reduc
risk
pathogen
transmiss
reduc
financi
risk
lose
entir
lot
igg
concentr
mani
decad
develop
igg
fraction
driven
achiev
intraven
toler
increas
recoveri
puriti
concentr
today
two
differ
main
method
place
fraction
plasma
coldethanol
fraction
ionexchang
chromatographi
process
fig
appli
either
method
frozen
plasma
thaw
part
remain
insolubl
separ
repres
cryoprecipit
harbor
blood
coagul
factor
level
b
fig
supernat
cryopoor
plasma
contain
wide
array
plasma
protein
includ
immunoglobulin
albumin
coldethanol
fraction
either
accord
cohnoncley
kistlernitschmann
oncley
et
al
nitschmann
et
al
see
chap
well
cryopoor
plasma
precipit
obtain
contain
immunoglobulin
level
b
fig
supernat
start
materi
albumin
fraction
suspensionprecipit
step
precipit
contain
fig
estim
risk
undetect
donat
enter
blood
suppli
mass
screen
serolog
nat
perform
addit
offergeld
et
al
reciproc
risk
rate
undetect
infecti
donat
given
higher
bar
lower
risk
rate
immunoglobulin
final
end
term
igg
bulk
level
c
fig
crude
igg
concentr
undergo
variou
polish
step
tabl
polish
step
final
formul
differ
among
variou
compani
level
e
fig
earli
standard
igg
concentr
underw
polish
step
igg
bulk
materi
contain
aggreg
render
toler
appli
intraven
typic
im
product
solut
strength
introduc
viru
inactivationremov
step
origin
manufactur
process
product
surviv
day
first
gener
igg
product
intraven
use
ivig
depriv
unwant
fceffector
function
harsh
enzym
treatment
digest
igg
molecul
heavili
impair
biolog
function
howev
well
toler
one
product
still
avail
post
japanes
websit
see
chap
second
gener
ivig
intact
igg
molecul
chemic
modifi
order
prevent
overt
spontan
complement
activ
recipi
circul
chemic
modifi
product
still
avail
region
market
mention
chap
book
third
gener
ivig
made
intraven
toler
gentl
polish
step
level
fig
although
mani
aspect
excel
two
coldethanol
fraction
method
reach
limit
push
improv
recoveri
without
loss
puriti
reason
plasma
industri
move
toward
ionexchang
chromatographi
fraction
igg
manufactur
method
allow
rel
high
recoveri
high
puriti
cryopoor
plasma
intermedi
fraction
depriv
albumin
fed
onto
ionexchang
column
must
free
lipid
level
b
tabl
polish
step
achiev
particular
properti
clinic
applic
igg
eg
intraven
toler
polyethylen
glycol
precipit
remov
aggreg
ph
trace
pepsin
alter
aggreg
low
ph
viru
inactiv
step
ph
viru
inactiv
reduct
aggreg
depthultradiafiltr
confound
viru
filtrat
depth
filtrat
use
filter
precipit
protein
separ
supernat
use
filter
aid
filter
aid
help
maintain
high
flow
rate
filter
process
time
may
adsorb
pathogen
pathogenprotein
complex
quit
effici
predominantli
appli
coldethanol
prepar
crude
igg
remov
aggreg
adsorb
virus
diafitr
serv
remov
eg
salt
igg
solut
help
semiperm
membran
ultrafiltr
use
pressur
concentr
gradient
semiperm
membran
reduct
isoagglutinin
antia
antib
immunoaffin
chromatographi
step
dhainaut
et
al
et
al
elev
isoagglutinin
titer
associ
chromatograph
fraction
method
reduct
rate
hemolyt
advers
event
fig
wide
use
techniqu
get
rid
lipid
octano
acid
capryl
acid
precipit
capryl
acid
precipit
first
use
combin
deae
cellulos
column
isol
igg
plasma
good
yield
steinbuch
audran
chromatograph
fraction
lipidfre
plasma
undergo
sever
anionandor
cationexchang
chromatographi
step
bertolini
dhainaut
et
al
cramer
et
al
trejo
et
al
result
igg
solut
undergo
polish
step
order
achiev
toler
tabl
chromatograph
obtain
prepar
elev
frequenc
hemolyt
reaction
emerg
advers
event
suppos
relat
presenc
higher
titer
isoagglutinin
seen
product
obtain
coldethanol
fraction
order
reduc
level
isoagglutinin
antia
antib
particular
polish
step
introduc
manufactur
immunoaffin
chromatographi
use
column
correspond
trisaccharid
coupl
matrix
dhainaut
et
al
et
al
et
al
donor
select
mass
screen
implement
ad
voluntari
qualiti
measur
import
pathogen
safeti
plasma
product
howev
far
suffici
optim
safeti
bill
build
safeti
fraction
process
final
render
product
pathogen
safe
among
stabl
plasma
product
manufactur
igg
concentr
offer
step
effect
enough
reduc
inactiv
virus
without
harm
much
biolog
function
molecul
inde
igg
concentr
larg
remain
free
transmit
virus
remark
patient
impair
immun
defens
may
requir
monthli
administr
immunoglobulin
lifelong
patient
autoimmuneinflammatori
diseas
might
requir
high
high
dose
immunoglobulin
therapi
sometim
prolong
period
nevertheless
remain
viru
free
besid
donor
select
mass
screen
third
pillar
pathogen
safeti
built
reduct
potenti
present
pathogen
manufactur
level
b
c
fig
either
exist
fraction
step
valid
accordingli
dedic
viru
inactivationremov
step
introduc
manufactur
process
aspect
valid
process
outlin
tabl
three
principl
differ
mechan
contribut
elimin
inactiv
virus
potenti
present
manufactur
plasma
product
kempf
et
al
name
valid
studi
perform
laboratori
scale
implement
downscal
fraction
process
labscal
process
undergo
valid
demonstr
critic
paramet
step
correspond
largescal
laboratori
condit
b
viru
stock
tabl
model
virus
select
biolog
physiolog
similar
plasmaborn
virus
well
character
size
puriti
aggreg
level
term
model
viru
defin
virus
use
valid
studi
grown
cell
cultur
event
human
pathogen
safeti
reason
use
human
pathogen
virus
larg
avoid
must
cover
wide
rang
physicochem
properti
virus
effort
test
abil
system
cope
pathogen
divers
eg
envelop
nonenvelop
variou
size
dna
rna
virus
virus
high
resist
physicochem
treatment
anim
virus
physicochem
properti
close
resembl
human
pathogen
virus
interest
repres
rang
physicochem
properti
wide
ever
possibl
viru
stock
high
titer
valid
igg
manufactur
process
crossreact
antibodi
viru
use
alway
consid
c
cell
cultur
read
assay
system
conveni
ie
cell
cultiv
easi
sensit
viru
high
read
system
conveni
electron
document
cell
cultur
best
prepar
micro
titer
plate
stain
cell
destroy
viru
valid
partit
filtrat
step
start
materi
spike
correspond
viru
spike
materi
assess
infect
ie
spike
materi
dilut
tenfold
log
dilut
step
titrat
tissu
cultur
infecti
dose
tcid
result
materi
eg
precipit
supernat
filtrat
retain
materialsolut
separ
test
residu
infect
descri
logarithm
reduct
factor
lrf
viru
calcul
follow
log
inocul
viru
log
residu
viru
eg
supernat
sum
residu
viru
infect
found
eg
supernat
precipit
must
equal
titer
inocul
case
either
explan
found
explan
valid
valid
fail
e
valid
viru
inactiv
step
inocul
materi
incub
chang
appropri
paramet
temperatur
aliquot
taken
variou
incub
time
aliquot
assess
remain
infect
kinet
viru
inactiv
calcul
appropri
result
proven
calcul
inactiv
constant
transform
natur
logarithm
plot
reciproc
absolut
temperatur
arrheniu
plot
fit
calcul
valu
regress
line
excel
intern
control
qualiti
data
inactiv
solventdeterg
sd
treatment
disrupt
viru
envelop
capryl
octano
acid
treatment
treatment
low
ph
destruct
conform
chang
structur
protein
heat
dri
wet
wet
pasteur
disrupt
envelop
destruct
conform
chang
structur
protein
eg
capsid
protein
elimin
base
size
viru
filtrat
formerli
term
nanofiltr
elimin
larg
scale
possibl
contamin
pathogen
base
size
recent
techniqu
free
plasma
product
form
pathogen
viru
filtrat
larg
scale
introduc
central
laboratori
swiss
red
cross
blood
transfus
servic
late
viru
filtrat
modest
size
stucki
et
al
viru
filtrat
larg
scale
submiss
dossier
sandoglobulin
nf
progress
manufactur
filter
smaller
smaller
pore
viru
filtrat
becom
univers
key
process
assur
pathogen
safetys
matter
virus
use
valid
studi
well
character
size
repres
close
possibl
virus
might
present
plasma
cover
wide
rang
physicochem
properti
virus
eg
envelop
nonenvelop
variou
size
dna
rna
virus
virus
high
resist
physicochem
treatment
valid
studi
immunoglobulin
care
taken
result
mislead
due
presenc
crossreact
andor
neutral
antibodi
b
although
human
pathogen
virus
grown
cell
cultur
consid
model
partit
eg
viru
precipit
supernat
process
filtrat
filter
aid
take
advantag
filter
aid
tightli
bind
adsorb
virus
precipit
despit
small
size
retain
technic
term
depth
filtrat
partit
involv
filtrat
techniqu
confound
viru
filtrat
dedic
viru
remov
principl
highest
level
product
safeti
achiev
three
principl
appli
stepwis
dilig
manner
fraction
process
tabl
exampl
lrf
obtain
variou
method
list
tabl
lfr
obtain
basi
vari
principl
addit
defin
safeti
margin
entir
manufactur
process
result
publish
variou
manufactur
variou
viru
inactiv
remov
step
allow
conclud
appli
variou
techniqu
sequenti
inactiv
envelop
virus
usual
achiev
well
current
inactiv
method
show
limit
effici
nonenvelop
virus
viru
filtrat
potenti
complet
remov
smallest
robust
nonenvelop
virus
known
partit
process
addit
contribut
viral
safeti
combin
pathogen
elimin
method
also
provid
confid
variou
fraction
process
cope
newli
emerg
virus
far
proven
transmiss
igg
concentr
emerg
virus
last
two
decad
occur
might
credit
tightli
implement
qa
framework
emerg
pathogen
predominantli
zoonot
natur
henc
reservoir
anim
emerg
associ
hygien
condit
transmiss
envelop
zoonot
virus
speci
barrier
sever
consequ
man
describ
chikungunya
viru
mer
coronaviru
avian
influenza
viru
bird
flu
sar
coronaviru
west
nile
viru
ebola
viru
zika
viru
other
presenc
virus
blood
donor
report
west
nile
viru
sar
coronaviru
zika
viru
persist
cellular
blood
compart
valid
studi
assur
safeti
regard
transmiss
plasma
product
relev
envelop
zoonot
virus
tabl
gener
envelop
virus
rel
easili
inactiv
eg
solventdeterg
treatment
nonenvelop
virus
gene
mutat
prerequisit
cross
speci
barrier
hepat
e
viru
hev
nonenvelop
zoonot
viru
pig
four
genotyp
known
genotyp
recogn
zoonot
pathogen
industri
countri
transmiss
pork
blood
rare
cook
meat
transmiss
hev
plasma
exchang
report
mallet
et
al
prevent
hev
transmiss
relev
infect
sever
neurolog
consequ
even
immunocompet
individu
blascoperrin
et
al
higuchi
et
al
torr
et
al
scanvion
et
al
elimin
inactiv
hev
manufactur
plasma
product
appar
suffici
prevent
pathogen
transmiss
tabl
gener
nonenvelop
virus
mutat
slowli
one
known
except
dna
parvovirida
show
similar
mutat
frequenc
rna
virus
boschetti
et
al
shackelton
holm
distinct
immun
adapt
pressur
specif
amino
acid
chang
parvovirus
endow
tropism
shift
anim
world
lopezbueno
et
al
henc
new
variantsspeci
tropism
expect
theoret
small
nonenvelop
virus
repres
biggest
threat
transfus
incid
futur
hope
techniqu
viru
filtrat
suffici
improv
elimin
eventu
emerg
parvovirida
human
tropism
also
anim
origin
agent
variant
creutzfeldtjakob
diseas
vcjd
tse
vcjd
great
certainti
transmit
cow
mad
cow
diseas
bovin
spongiform
enceph
bse
human
bruce
et
al
bse
emerg
due
optim
product
process
anim
carcassderiv
materi
fed
cow
wilesmith
et
al
form
human
spongiform
encephalitid
exist
iatrogenicsporad
inheritedgenet
acquiredinfecti
tabl
spongiform
encephalitid
mediat
misfold
isoform
scrapi
normal
cellular
prion
protein
prp
c
ubiquit
cell
protein
highli
conserv
evolut
misfold
scrapi
prion
protein
prp
sc
studi
provid
solid
reassur
safeti
plasma
product
regard
emerg
virus
furthermor
result
verifi
use
model
virus
appropri
predict
inactiv
characterist
newli
emerg
virus
physicochem
properti
well
character
result
fatal
neurodegen
diseas
mammal
although
proteinonli
agent
prp
sc
infecti
sens
misfold
protein
might
induc
conform
chang
normal
prp
c
result
sticki
rodlik
fibrillari
particl
accumul
brain
serum
plasma
leukocyt
vcjd
patient
might
harbor
infecti
prp
sc
inde
transmiss
prp
sc
report
three
symptomat
one
nonsymptomat
case
nonleukocytedeplet
red
blood
cell
concentr
hewitt
et
al
peden
et
al
measur
elimin
possibl
contamin
prp
sc
plasma
fraction
becam
mandatori
accept
inactiv
prp
sc
possibl
without
destruct
biolog
activ
plasma
product
henc
elimin
partit
exclus
size
remain
two
possibl
cai
et
al
valid
studi
perform
differ
manufactur
site
differ
spike
differ
detect
system
manufactur
step
studi
remov
capac
prp
sc
includ
precipit
adsorpt
chromatographi
filtrat
well
combin
step
prove
highli
potent
remov
tse
agent
possibl
contamin
plasma
cai
et
al
reduct
individu
step
sequenc
addit
pathogen
prion
protein
almost
exclus
locat
cn
pathogen
prion
protein
found
cn
also
abund
lymphat
tissu
furthermor
declin
incid
vcjd
stringent
donor
select
due
geograph
donor
deferr
polici
addit
natur
remov
step
render
agent
vcjd
unlik
transmit
plasma
product
inde
proven
transmiss
vcjd
igg
concentr
ever
report
ritchi
et
al
even
administr
possibl
prp
sc
contamin
igg
concentr
occur
elshanawani
et
al
ascertain
transmiss
plasma
product
describ
neither
sporadiciatrogen
cjd
scjd
vcjd
tabl
scjd
repres
spongiform
encephalitid
human
affect
elderli
peopl
exist
sever
surveil
studi
transmiss
scjd
blood
blood
product
conduct
american
red
cross
uk
franc
crowder
et
al
martin
trouvin
urwin
et
al
studi
report
scjd
patient
popul
treat
blood
plasma
product
basi
consid
scjd
transmiss
blood
transfus
plasma
product
howev
emerg
infecti
diseas
journal
may
post
electron
form
report
two
patient
receiv
coagul
factor
concentr
die
scjd
author
conclud
citat
causal
link
treatment
plasma
product
develop
scjd
establish
occurr
case
may
simpli
reflect
chanc
event
context
systemat
surveil
cjd
larg
popul
outmost
import
whether
mani
new
case
report
futur
final
formul
ensur
stabilitytoler
product
shelf
life
right
select
stabil
particular
import
product
lyophil
freezedri
basic
physicochem
process
freezedri
replac
layer
water
surround
igg
molecul
layer
also
term
hydrat
shell
hydrat
sphere
keep
igg
molecul
solut
makarov
et
al
dehydr
product
eg
oxid
prepar
larg
prevent
aggreg
dimer
format
suppress
henc
excipi
part
serv
stabil
freezedri
product
major
role
make
sure
lyophil
protein
reconstitut
entir
within
reason
time
aggreg
remain
compound
inject
intraven
best
physicochem
properti
simul
water
sugar
follow
amino
acid
although
associ
osmot
nephrosi
patient
risk
sever
lyophil
product
contain
sucros
still
market
see
also
chap
respons
request
conveni
handl
liquid
prepar
develop
liquid
prepar
age
continu
interact
molecul
inher
stabil
preserv
characterist
without
hamper
qualiti
prevent
oxid
iggigg
interact
eg
limit
igg
dimer
format
wide
use
stabil
liquid
prepar
glycin
lprolin
maltos
sorbitol
clean
sanit
product
line
prevent
crosscontamin
surfaceadsorb
infecti
agent
measur
taken
cgmp
clean
valid
involv
infecti
agent
problemat
eg
clean
process
scale
case
imposs
eg
rheolog
properti
differ
small
scale
typic
naoh
sodium
hypochlorit
naclo
use
plant
sanit
run
appropri
concentr
suffici
destroy
viru
infect
howev
tse
agent
vcjd
need
particular
effort
show
sanit
measur
destroy
tse
agent
prp
sc
prp
re
serv
purpos
tabl
valid
strategi
show
prp
re
naoh
naclo
exposur
becom
one
hand
noninfecti
hand
sensit
proteinas
k
digest
naoh
naclo
treatment
destroy
prp
re
even
low
naoh
naclo
concentr
regulatori
agenc
consid
current
clean
regim
adequ
assur
batchtobatch
segreg
traceabl
gmp
requir
blood
plasma
deriv
includ
traceabl
batch
donor
recipi
industri
respons
interlink
given
batch
plasma
product
inform
respons
donor
given
medic
questionnair
result
mass
screen
pool
inform
traceabl
also
interconnect
batch
hospit
product
deliv
respons
hospit
complet
traceabl
document
ivig
batch
given
individu
patient
prp
sc
gener
term
aberrantli
fold
infecti
prion
protein
refer
exclus
suspect
agent
scrapi
sheep
enabl
look
back
case
problem
identifi
donor
recipi
end
basi
traceabl
bar
code
identif
system
proper
traceabl
system
ensur
lot
recal
necessari
allow
handl
postdon
inform
pharmacovigil
effici
safe
manner
obtain
final
proof
clinic
efficaci
pathogen
safeti
igg
concentr
qualiti
assur
surveil
program
extend
product
qualiti
distribut
pharmacovigil
postmarket
studi
surveil
program
pillar
final
proof
qualiti
igg
concentr
stand
pharmacovigil
ensur
continu
safeti
medicin
product
use
collect
monitor
assess
type
advers
drug
reaction
relat
product
ball
et
al
http
eceuropaeuhealthhumanusepharmacovigilanceen
infect
incub
time
might
long
surveil
program
current
mean
conclus
obtain
longrang
safeti
inform
clinician
encourag
report
advers
event
especi
unexpect
unusu
